NCT06017869View on ClinicalTrials.gov

Evaluate the Safety and Therapeutic Effects of a Single Intravenous Infusion (IV) of Autologous CD34+ Cells Enriched With Allogenic Placenta-derived Mitochondria in Patients With a Diagnosis of Pearson Syndrome (PS)

PHASE2RecruitingINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

July 31, 2023

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2027

Conditions
Mitochondrial DiseasesPearson Syndrome
Interventions
BIOLOGICAL

MNV-201

Autologous CD34+ cells are isolated from the participant's peripheral blood after mobilization by leukapheresis. Allogeneic mitochondria are isolated under aseptic conditions from healthy donor placenta, cryopreserved and qualified before use.

Trial Locations (1)

5266202

RECRUITING

Sheba Medical Center, Ramat Gan

Sponsors
All Listed Sponsors
lead

Minovia Therapeutics Ltd.

INDUSTRY

NCT06017869 - Evaluate the Safety and Therapeutic Effects of a Single Intravenous Infusion (IV) of Autologous CD34+ Cells Enriched With Allogenic Placenta-derived Mitochondria in Patients With a Diagnosis of Pearson Syndrome (PS) | Biotech Hunter | Biotech Hunter